SCHEMBL2959372

SCHEMBL2959372

CC(C)C1CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118865 1.00
SCHEMBL28838630 1.00
SCHEMBL1614979 0.96
SCHEMBL15670203 0.96
SCHEMBL23802808 0.96
SCHEMBL23802763 0.96
Bromide SCHEMBL15670239 0.93
SCHEMBL23126402 0.83
SCHEMBL21910170 0.83
SCHEMBL10979288 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627868-B1 Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2007-12-19 EP claimed
CN-1865229-A Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2006-11-22 CN claimed
EP-1627868-A2 Aspartic ester functional compounds Bayer MaterialScience LLC (US) 2006-02-22 EP claimed
US-20060011295-A1 Aspartic ester functional compounds BAYER MATERIAL SCIENCE LLC 2006-01-19 US claimed
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
US-20230382923-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-11-30 US disclosed
US-20230382923-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-11-30 US disclosed
US-11807649-B2 Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 ENLIVEN THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11807649-B2 Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 ENLIVEN THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
WO-2023178204-A1 ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS YALE UNIVERSITY (US) 2023-09-21 WO disclosed
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
WO-2023141300-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-07-27 WO disclosed
EP-0095906-B1 IMPROVEMENTS RELATING TO COMPOUNDS USEFUL IN RADIOTHERAPY OR CHEMOTHERAPY NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1986-10-22 EP disclosed
US-4596817-A Chemopotentiating agents NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1986-06-24 US disclosed
US-4581368-A ANTICARCINOGENIC AGENT POTENTIATORS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1986-04-08 US disclosed
US-4578195-A Process for the purification of effluents and purge streams containing trace elements OLIN CORPORATION (US) 1986-03-25 US disclosed
US-4518760-A FROM A POLYIMINE AND A POLYISOCYANATE THROUGH A POLYAMINEPOLYUREA INTERMEDIATE, REACTED WITH AMMONIUM HYDROXIDE AND CARBON DISULFIDE OLIN CORPORATION (US) 1985-05-21 US disclosed
EP-0095906-A1 Improvements relating to compounds useful in radiotherapy or chemotherapy NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1983-12-07 EP disclosed
US-4337154-A FORMED FROM A POLYALKYLENIMINE AND A NITROGEN-HETEROCYCLIC SECONDARY AMINE COMPOUND NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) 1982-06-29 US disclosed
US-3998808-A INSECTICIDES, FUNGICIDES VELSICOL CHEMICAL CORPORATION (US) 1976-12-21 US disclosed